AFRICAN AMERICAN ANTIPLATELET STROKE PREVENTION STUDY (AAASPS)

这是一项IV期、多中心、双盲临床试验，目的是比较噻氯匹定和阿司匹林在非裔美国人轻度或中度神经功能缺损的非心源性缺血性中风患者中的疗效和安全性。中风是严重影响非裔美国人的疾病之一（与白人相比，非裔美国人死于中风或经历中风的可能性大约是白人的2.5倍）。对非白人，主要是非裔美国人的神经缺血患者的初步研究表明，盐酸噻氯匹定（FDA批准的市售抗血小板药物）在预防非白人患者中风和死亡方面比阿司匹林更有效。因此，本研究的具体目的是比较非洲裔美国卒中患者的两个治疗组（一组随机接受阿司匹林治疗，另一组随机接受噻氯匹定治疗）复发性卒中、心肌梗死和血管性死亡的主要结局终点。该研究旨在评估两种药物在研究人群中风治疗和预防方面的有效性和安全性。

This is a phase IV, multicenter, double-blind clinical trial to compare the efficacy and safety of Ticlopidine and Aspirin among African American non-cardioembolic ischemic stroke patients with mild or moderate neurological deficits. Stroke is one of the diseases that disproportionately afflicts African Americans (African Americans are about 2.5 times more likely to die of stroke or experience stroke , as compared to their white counterparts). Preliminary studies on nonwhite, predominantly African American cerecral ischemia patients suggest that Ticlopidine hydrochloride, an FDA approved and commercially available antiplatelet agent is more effective than aspirin in the prevention of stroke and death among nonwhite patients. Thus, the Specific Aim of this study is to compare the primary outcome endpoints of recurrent stroke, myocardial infarction and vascular deaths among two treatment groups (one group randomized to aspirin therapy and the other randomized to ticlopidine therapy) of African American stroke patients. The study is designed to assess the efficacy and safety of both drugs on stroke treatment and prevention in the population studied.